CAR T-cell therapy has demonstrated tremendous success in the treatment of certain hematologic malignancies and is now being studied in solid tumors, including PCa, with limited progress due to numerous challenges including complexities inherit to the immune microenvironment of various solid tumors.19–23 Early studies of CAR-T in PCa include multiple ongoing phase I studies including a PSCA-targeted 4-1BB-co-stimulated CAR T-cell therapy (NCT05805371) and multiple PSMA-targeting CAR T-cell therapies (NCT03089203, NCT04249947).24,25. Here, FOLH1 is linked to posterior cortical atrophy.